2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure

Chun Chieh Wang, Cho Kai Wu, Ming Lung Tsai, Chii Ming Lee, Wei Chun Huang, Hsin Hua Chou, Jin Long Huang, Nai Hsin Chi, Hsueh Wei Yen, Bing Hsiean Tzeng, Wei Ting Chang, Hung Yu Chang, Chao Hung Wang, Yen Yu Lu, Jui Peng Tsai, Chun Hung Su, Wen Jin Cherng, Wei Hsian Yin, Chia Ti Tsai, Yen Wen WuJiunn-Lee Lin, Juey Jen Hwang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Heart failure is a growing epidemic, especially in Taiwan because of the aging population. The 2016 Taiwan Society of Cardiology - Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry showed that the guidelinerecommended therapies were prescribed suboptimally both at the time of hospital discharge and during followup. We, therefore, conducted this 2019 focused update of the guidelines of the Taiwan Society of Cardiology for the diagnosis and treatment of heart failure to reinforce the importance of new diagnostic and therapeuticmodalities of heart failure. The 2019 focused update discusses new diagnostic criteria, pharmacotherapy, non-pharmacological management, and certain co-morbidities of heart failure. Angiotensin receptor neprilysin inhibitor and If channel inhibitor is introduced as new and recommended medical therapies. Latest criteria of cardiac resynchronization therapy, implantable cardioverter-defibrillator, heart transplantation, and ventricular assist device therapy are reviewed in the non-pharmacological management chapter. Co-morbidities in heart failure are discussed including chronic kidney disease, diabetes, chronic obstructive pulmonary disease, and sleep-disordered breathing.We also explain the adequate use of oxygen therapy and non-invasive ventilation in heart failure management. A particular chapter for chemotherapy-induced cardiac toxicity is incorporated in the focused update to emphasize the importance of its recognition and management. Lastly, implications from the TSOC-HFrEF registry and post-acute care of heart failure are discussed to highlight the importance of guideline-directed medical therapy and the benefits of multidisciplinary disease management programs. With guideline recommendations, we hope that the management of heart failure can be improved in our society.

Original languageEnglish
Pages (from-to)244-283
Number of pages40
JournalActa Cardiologica Sinica
Volume35
Issue number3
DOIs
Publication statusPublished - May 1 2019

    Fingerprint

Keywords

  • Biomarkers
  • Cardiac resynchronization therapy
  • Cardio-oncology
  • Co-morbidities
  • Guidelines
  • Heart failure
  • Pharmacotherapy
  • Post-acute care
  • Transplantation
  • Ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wang, C. C., Wu, C. K., Tsai, M. L., Lee, C. M., Huang, W. C., Chou, H. H., Huang, J. L., Chi, N. H., Yen, H. W., Tzeng, B. H., Chang, W. T., Chang, H. Y., Wang, C. H., Lu, Y. Y., Tsai, J. P., Su, C. H., Cherng, W. J., Yin, W. H., Tsai, C. T., ... Hwang, J. J. (2019). 2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure. Acta Cardiologica Sinica, 35(3), 244-283. https://doi.org/10.6515/ACS.201905_35(3).20190422A